Nucleus Genomics has established an IVF+ partnership with the Fertility Institute of Hawaii, Hawaii's largest IVF practice. This venture brings advanced carrier screening and embryo analysis to patients in the state and to international clients who travel from Japan, Korea, China, Australia, and New Zealand for fertility care.
Thanks to the collaboration between Nucleus Genomics and the Fertility Institute of Hawaii, patients undergoing in vitro fertilization can obtain deeper genetic insights into their embryos, including risk assessments for conditions such as cancer, heart disease, diabetes, endometriosis, type 1 diabetes, breast cancer, and Alzheimer's disease. Nucleus Genomics’ services — Preview and Embryo — screen for more than 2,000 genetic conditions and traits. The company’s statistics show decreases of nearly 32% for endometriosis, 67% for type 1 diabetes, 42% for breast cancer, 35% for heart disease, and 55% for Alzheimer’s disease.
The growing demand for such services, reflected in Nucleus's waitlist of over 3,000 patients and its rapid expansion of clinic partnerships across multiple states and countries, indicates a broader cultural shift toward precision medicine and personalized reproductive care.
Genetic Insight IVF Partnerships
Nucleus Genomics Partners with the Fertility Institute of Hawaii
Trend Themes
-
Genetic Embryo Profiling — Advanced embryo screening is expanding IVF decision-making beyond viability toward long-term disease risk visibility and personalized reproductive planning.
-
Cross-border Fertility Care — International patient travel for IVF is creating demand for clinics that combine destination healthcare with specialized genomic testing services.
-
Preventive Reproductive Medicine — Precision fertility services are reframing conception as an early intervention point for reducing inherited health risks across future generations.
Industry Implications
-
Fertility Clinics — IVF providers are gaining new differentiation through integrated genetic intelligence that supports more personalized patient consultations and treatment pathways.
-
Genomic Testing — Consumer and clinical genomics companies are moving into reproductive health with expanded screening platforms covering thousands of conditions and traits.
-
Medical Tourism — Fertility-focused travel markets are being reshaped by patients seeking advanced reproductive technologies unavailable or less accessible in their home countries.